• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

侵袭性与惰性胰岛素瘤:新的临床病理见解

Aggressive versus indolent insulinomas: new clinicopathological insights.

作者信息

Hackeng Wenzel M, Brosens Lodewijk A A, Dreijerink Koen M A

机构信息

Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.

Department of Endocrinology, Amsterdam University Medical Centers, VU University Medical Center, Amsterdam, The Netherlands.

出版信息

Endocr Relat Cancer. 2023 Mar 27;30(5). doi: 10.1530/ERC-22-0321. Print 2023 May 1.

DOI:10.1530/ERC-22-0321
PMID:36779771
Abstract

Insulinomas are rare functional pancreatic neuroendocrine tumors. While most insulinomas are indolent and cured after surgery, 10-15% of cases show aggressive or malignant tumor behavior and metastasize locally or to distant organs. Patients with metastatic insulinoma survive significantly shorter. Recognizing aggressive insulinomas can help to predict prognosis, guide therapy and determine follow-up intensity after surgery. This review offers a summary of the literature on the significant clinical, pathological, genetic and epigenetic differences between indolent and aggressive insulinomas. Aggressive insulinomas are characterized by rapid onset of symptoms, larger size, expression of ARX and alpha-1-antitrypsin and decreased or absent immunohistochemical expression of insulin, PDX1 and GLP-1R. Moreover, aggressive insulinomas often harbor ATRX or DAXX mutations, the alternative lengthening of telomeres phenotype and chromosomal instability. Tumor grade and MEN1 and YY1 mutations are less useful for predicting behavior. Aggressive insulinomas have similarities to normal alpha-cells and non-functional pancreatic neuroendocrine tumors, while indolent insulinomas remain closely related to normal beta-cells. In conclusion, indolent and aggressive insulinoma are different entities, and distinguishing these will have future clinical value in determining prognosis and treatment.

摘要

胰岛素瘤是罕见的功能性胰腺神经内分泌肿瘤。虽然大多数胰岛素瘤生长缓慢,手术后可治愈,但10% - 15%的病例表现出侵袭性或恶性肿瘤行为,并发生局部转移或远处器官转移。转移性胰岛素瘤患者的生存期明显较短。识别侵袭性胰岛素瘤有助于预测预后、指导治疗并确定术后随访强度。本综述总结了关于惰性和侵袭性胰岛素瘤在临床、病理、遗传和表观遗传方面显著差异的文献。侵袭性胰岛素瘤的特征为症状出现迅速、肿瘤体积较大、ARX和α1抗胰蛋白酶表达、胰岛素、PDX1和GLP - 1R免疫组化表达降低或缺失。此外,侵袭性胰岛素瘤常存在ATRX或DAXX突变、端粒替代延长表型和染色体不稳定。肿瘤分级以及MEN1和YY1突变对预测肿瘤行为的作用较小。侵袭性胰岛素瘤与正常α细胞和无功能性胰腺神经内分泌肿瘤有相似之处,而惰性胰岛素瘤仍与正常β细胞密切相关。总之,惰性和侵袭性胰岛素瘤是不同的实体,区分它们在确定预后和治疗方面将具有未来临床价值。

相似文献

1
Aggressive versus indolent insulinomas: new clinicopathological insights.侵袭性与惰性胰岛素瘤:新的临床病理见解
Endocr Relat Cancer. 2023 Mar 27;30(5). doi: 10.1530/ERC-22-0321. Print 2023 May 1.
2
Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas.端粒的替代性延长和内分泌转录因子的差异表达可区分转移性和非转移性胰岛素瘤。
Endocr Pathol. 2020 Jun;31(2):108-118. doi: 10.1007/s12022-020-09611-8.
3
Metastatic insulinoma: exploration from clinicopathological signatures and genetic characteristics.转移性胰岛素瘤:基于临床病理特征和基因特性的探究
Front Oncol. 2023 May 12;13:1109330. doi: 10.3389/fonc.2023.1109330. eCollection 2023.
4
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.无功能性胰腺神经内分泌肿瘤:ATRX/DAXX 和端粒的非经典延长(ALT)与 ARX/PDX1 表达和肿瘤大小无关,具有独立的预后价值。
Gut. 2022 May;71(5):961-973. doi: 10.1136/gutjnl-2020-322595. Epub 2021 Apr 13.
5
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres).产生胰高血糖素的胰腺神经内分泌肿瘤(胰高血糖素瘤)富含具有ARX和PDX1共表达、DAXX/ATRX突变以及端粒替代延长(ALT)的侵袭性肿瘤。
Endocr Pathol. 2024 Dec;35(4):354-361. doi: 10.1007/s12022-024-09826-z. Epub 2024 Sep 27.
6
Approach to the Patient: Insulinoma.患者评估:胰岛素瘤。
J Clin Endocrinol Metab. 2024 Mar 15;109(4):1109-1118. doi: 10.1210/clinem/dgad641.
7
Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.DAXX 和 ATRX 的缺失与染色体不稳定性和胰腺神经内分泌肿瘤患者的生存降低有关。
Gastroenterology. 2014 Feb;146(2):453-60.e5. doi: 10.1053/j.gastro.2013.10.020. Epub 2013 Oct 19.
8
Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas.人胰岛素瘤中胰高血糖素样肽-1 受体的免疫组织化学表达。
Int J Mol Sci. 2023 Oct 13;24(20):15164. doi: 10.3390/ijms242015164.
9
Chromosomal instability predicts metastatic disease in patients with insulinomas.染色体不稳定性可预测胰岛素瘤患者的转移性疾病。
Endocr Relat Cancer. 2005 Jun;12(2):435-47. doi: 10.1677/erc.1.00960.
10
Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup.胰腺神经内分泌肿瘤相关遗传变异和起源细胞的表观遗传变化洞察:实用检查算法
Cancers (Basel). 2022 Sep 13;14(18):4444. doi: 10.3390/cancers14184444.

引用本文的文献

1
Yin Yang 1 (YY1) as a Central Node in Drug Resistance Pathways: Potential for Combination Strategies in Cancer Therapy.阴阳1(YY1)作为耐药途径的核心节点:癌症治疗联合策略的潜力
Biomolecules. 2025 Jul 24;15(8):1069. doi: 10.3390/biom15081069.
2
A new link between insulinoma and congenital glucose-galactose malabsorption.胰岛素瘤与先天性葡萄糖-半乳糖吸收不良之间的新联系。
Endocr Oncol. 2025 Jul 11;5(1):e250030. doi: 10.1530/EO-25-0030. eCollection 2025 Jan.
3
Alpha thalassemia/mental retardation X-linked (ATRX) protein expression in human pituitary neuroendocrine tumours and its reported correlation to prognosis and clinical outcomes: A systematic review.
X连锁α地中海贫血/智力发育迟缓(ATRX)蛋白在人垂体神经内分泌肿瘤中的表达及其与预后和临床结局的相关性:一项系统评价
PLoS One. 2025 May 29;20(5):e0313380. doi: 10.1371/journal.pone.0313380. eCollection 2025.
4
Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors.ATRX/DAXX基因突变与丙氨酸转氨酶在功能性胰腺神经内分泌肿瘤中的临床相关性
Endocr Pathol. 2025 Feb 15;36(1):3. doi: 10.1007/s12022-025-09848-1.
5
A Rare and Aggressive Case of Malignant Insulinoma.一例罕见的侵袭性恶性胰岛素瘤病例。
Cureus. 2024 Nov 15;16(11):e73719. doi: 10.7759/cureus.73719. eCollection 2024 Nov.
6
A Comprehensive Target Panel Allows to Extend the Genetic Spectrum of Neuroendocrine Tumors.一个综合的靶向检测板有助于扩展神经内分泌肿瘤的基因谱。
Neuroendocrinology. 2025;115(5):381-401. doi: 10.1159/000542223. Epub 2024 Nov 13.
7
Metastatic insulinoma-outcomes in the current era.转移性胰岛素瘤——当代的治疗结果
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyae275.
8
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres).产生胰高血糖素的胰腺神经内分泌肿瘤(胰高血糖素瘤)富含具有ARX和PDX1共表达、DAXX/ATRX突变以及端粒替代延长(ALT)的侵袭性肿瘤。
Endocr Pathol. 2024 Dec;35(4):354-361. doi: 10.1007/s12022-024-09826-z. Epub 2024 Sep 27.
9
Insulinoma Unmasked: A Continuous Glucose Monitoring-Fueled Journey.胰岛素瘤揭秘:连续血糖监测驱动的探索之旅。
Curr Oncol. 2024 Sep 14;31(9):5452-5461. doi: 10.3390/curroncol31090403.
10
Approach to the Patient: Insulinoma.患者评估:胰岛素瘤。
J Clin Endocrinol Metab. 2024 Mar 15;109(4):1109-1118. doi: 10.1210/clinem/dgad641.